Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2006

01-12-2006 | Clinical Trial

Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19

Authors: Jianhua Liu, Dongsheng Tu, Janet Dancey, Leonard Reyno, Kathleen I. Pritchard, Joseph Pater, Lesley K Seymour

Published in: Breast Cancer Research and Treatment | Issue 3/2006

Login to get access
Metadata
Title
Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19
Authors
Jianhua Liu
Dongsheng Tu
Janet Dancey
Leonard Reyno
Kathleen I. Pritchard
Joseph Pater
Lesley K Seymour
Publication date
01-12-2006
Published in
Breast Cancer Research and Treatment / Issue 3/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9257-1

Other articles of this Issue 3/2006

Breast Cancer Research and Treatment 3/2006 Go to the issue

Preclinical Study

Direct-to-patient BRCA1 testing: the Twoj Styl experience

Clinical Epidemiology

Is risk of axillary lymph node metastasis associated with proximity of breast cancer to the skin?

Letter to the Editor

Lack of Association Between NOS3 Glu298Asp and Breast Cancer Risk: a Case–ontrol Study

Clinical Trial

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

Letter to the Editor

Albumin-Bound Paclitaxel, ABI-007 May Show Better Efficacy than Paclitaxel in Basal-Like Breast Cancers: Association Between Caveolin-1 Expression and ABI-007

Epidemiology

Cigarette smoking and breast cancer risk: update of a prospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits